CCR Grand Rounds
	January 25: Dr. Carter Van Waes, Clinical Director, National Institute on Deafness and Other Communication Disorders, Principal Investigator, Radiation Oncology Sciences Program, CCR, NCI; "Nuclear Factor-kappaB in Regulation of Gene Expression and as a Target for Molecular Therapy in Head and Neck Cancer" February 8: Dr. J. Carl Barrett, Director, CCR, NCI; "Biosystems and Cancer: Implications for Cancer Development and Therapy"

The new and returning members make up a group that has had personal and professional experience with cancer in a broad spectrum of disease sites, including kidney, ovarian, breast, and prostate cancers and leukemia and lymphoma. The members are active in survivor and community groups and represent underserved populations.

Launched in 1997, the DCLG - a federally chartered committee - was the first all-consumer advisory board at NIH. The DCLG's 15 members, headed by Doug Ulman, advise NCI's director about a wide variety of issues, programs, and research priorities from the perspective of people whose lives are affected by cancer. For more information and a listing of DCLG members, go to http://la.cancer.gov/dclg.html.

NCI Scientists to Speak at Gordon Conference
The Gordon Research Conferences will present "New Frontiers in Cancer Detection and Diagnosis" January 16-21, in Buellton, Calif.

Drs. J. Carl Barrett, Peter Greenwald, Richard Simon, and Sudhir Srivastava, all of NCI, will speak about molecular basis for early detection, biomarker validation methodology, and high throughput technology enabling cancer detection.

The Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences and their related technologies. For more information, go to http://www.grc.org/programs/2005/newfront.htm.

NCI Launches Nanotechnology Seminar Series
NCI will host a new lecture series featuring innovative perspectives on current research and development efforts in nanotechnology applied to cancer diagnosis, treatment, and prevention, presented by leaders from both the cancer and nanotechnology research communities. The inaugural lecture, to be held on Thursday, Jan. 27, will feature Dr. Esther Chang, professor of oncology and otolaryngology at the Lombardi Comprehensive Cancer Center. Her lecture, "Tumor Targeting Nanodelivery Systems: Expanding the Potential for Cancer Therapy and Diagnosis," will be held from 2:00 to 3:00 p.m. in Balcony B, Natcher (Building 45), on the NIH campus.

This presentation will be webcast at http://videocast.nih.gov. Sign language interpreters will be provided. For more information on the lecture, visit http://nano.cancer.gov/events_nanotech_seminar_series.asp.